Methods for isolating human cardiac ventricular progenitor cells

• US 10,508,263 B2
• Filed: 11/07/2017
• Issued: 12/17/2019
• Est. Priority Date: 11/29/2016
• Status: Active Grant

• Current Assignee: Procella Therapeutics AB
• Original Assignee: Procella Therapeutics AB
• Inventors: Chien, Kenneth R., Clarke, Jonathan, Lehtinen, Miia, Foo, Kylie, Leung, Chuen Yan
• Primary Examiner(s): Kim, Taeyoon
• Application Number:
  US15/805,463
• Publication Number:
  US 20180148691A1
• Time in Patent Office: 770 Days
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/42 Notch; Delta; Jagged; Serrate
• CPC Class Codes: C12N 2501/50 Cell markers; Cell surface determinants
• CPC Class Codes: C12N 2501/599 with CD designations not provided for elsewhere
• CPC Class Codes: C12N 2501/727 Kinases (EC 2.7.)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/45 from artificially induced pluripotent stem cells
• CPC Class Codes: C12N 2513/00 3D culture
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5061 Muscle cells

Abstract

The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.

Claims

1. A method for generating human ventricular muscle cells in vivo in a subject using engraftable human cardiac ventricular progenitor cells (HVPs), the method comprising:

contacting a culture of day 5-7 cardiac progenitor cells (CPCs) comprising HVPs with one or more first agents reactive with at least one first marker selected from the group consisting of TRA-1-60, TRA-1-81, TRA-2-54, SSEA1, SSEA3, SSEA4, CD9, CD24, E-cadherin, Podocalyxin, and combinations thereof, and with one or more second agents reactive with a second marker selected from the group consisting of JAG1, LIFR, FGFR3, TNFSF9 and combinations thereof, wherein the culture is contacted with the one or more second agents either before, simultaneously with or after contacting with the one or more first agents,

wherein the culture of day 5-7 CPCs has been obtained by subjecting human pluripotent stem cells to activation of Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5;

isolating first marker negative/second marker positive cells to thereby isolate a cell population comprising engraftable HVPs,

administering the cell population comprising engraftable HVPs to a subject;

wherein the cell population comprising engraftable HVPs forms a vascularized, electrically responsive ventricular muscle patch that secretes an extracellular matrix in the subject; and

detecting cardiac function in the subject indicative of engraftment of the isolated cell population comprising engraftable HVPs.

2. The method of claim 1, wherein the at least one first marker is TRA-1-60.

3. The method of claim 1, wherein the culture is a day 6 culture of cardiac progenitor cells.

4. The method of claim 1, wherein the culture is contacted with the one or more second agents before contact with the one or more first agents.

5. The method of claim 1, wherein the culture is contacted with the one or more second agents after contact with the one or more first agents.

6. The method of claim 1, wherein the culture is contacted with the one or more second agents simultaneously with contact with the one or more first agents.

7. The method of claim 1, wherein the first agent is an antibody that binds the first marker.

8. The method of claim 1, wherein the second agent is an antibody that binds the second marker.

9. The method of claim 1, wherein the first marker is TRA-1-60 and the second marker is LIFR.

10. The method of claim 1, wherein the first marker is TRA-1-60 and the second marker is JAG1.

11. The method of claim 1, wherein the first marker is TRA-1-60 and the second marker is FGFR3.

12. The method of claim 1, wherein the first marker is TRA-1-60 and the second marker is TNFSF9.

13. The method of claim 1, wherein the first marker negative/second marker positive cells are isolated by fluorescence activated cell sorting (FACS) or by magnetic activated cell sorting (MACS).

14. The method of claim 1, which further comprises culturing human pluripotent stem cells under conditions that generate cardiac progenitor cells (CPCs), wherein said conditions comprise activation of Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5, to obtain a culture of day 5-7 CPCs prior to contacting the culture of day 5-7 CPCs with the one or more first agents and the one or more second agents.

29. The method of claim 1, wherein ventricular muscle cells derived from the cell population comprising engraftable HVPs are detected by detecting expression of at least one ventricular marker.

30. The method of claim 29, wherein the at least one ventricular marker is selected from the group consisting of MLCv2, IRX4, HRT2 and combinations thereof.

31. The method of claim 1, wherein the cell population comprising engraftable HVPs are administered into the heart of the subject.

15. A composition comprising an isolated population of at least 1×

10⁶ purified engraftable human cardiac ventricular progenitor cells (HVPs), wherein the population of HVPs is derived from human embryonic stem (ES) cells or induced pluripotent stem cells (iPSC) and is;

(i) negative for at least one first marker selected from the group consisting of TRA-1-60, TRA-1-81, TRA-2-54, SSEA1, SSEA3, SSEA4, CD9, CD24, E-cadherin, Podocalyxin, and combinations thereof, and (ii) positive for at least one second marker selected from the group consisting of JAG1, LIFR, FGFR3 and TNFSF9, wherein the HVPs are complexed with at least one antibody that binds JAG1, LIFR, FGFR3 or TNFSF9.

16. A method for isolating a cell population comprising engraftable human cardiac ventricular progenitor cells (HVPs), the method comprising:

contacting a culture of day 5-7 cardiac progenitor cells (CPCs) comprising HVPs with one or more first agents reactive with a first marker selected from the group consisting of TRA-1-60, TRA-1-81, TRA-2-54, SSEA1, SSEA3, SSEA4, CD9, CD24, E-cadherin, Podocalyxin, and combinations thereof, and with one or more second agents reactive with a second marker selected from the group consisting of JAG1, LIFR, FGFR3, TNFSF9 and combinations thereof, wherein the culture is contacted with the one or more second agents either before, simultaneously with or after contacting with the one or more first agents;

wherein the culture of day 5-7 CPCs has been obtained by subjecting human embryonic stem (ES) cells or induced pluripotent stem cells (iPSC) to activation of Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5; and

isolating first marker negative/second marker positive cells to thereby isolate a cell population comprising engraftable HVPs.

17. The method of claim 16, wherein the first marker is TRA-1-60 and the second marker is LIFR.

18. The method of claim 16, wherein the first marker is TRA-1-60 and the second marker is JAG1.

19. The method of claim 16, wherein the first marker is TRA-1-60 and the second marker is FGFR3.

20. The method of claim 16, wherein the first marker is TRA-1-60 and the second marker is TNFSF9.

21. The method of claim 16, wherein the first agent is an antibody that binds the first marker.

22. The method of claim 16, wherein the second agent is an antibody that binds the second marker.

23. The method of claim 16, wherein the first marker negative/second marker positive cells are isolated by fluorescence activated cell sorting (FACS) or by magnetic activated cell sorting (MACS).

24. The method of claim 16, wherein the culture is a day 6 culture of cardiac progenitor cells.

25. The method of claim 16, wherein the culture is contacted with the one or more second agents before contact with the one or more first agents.

26. The method of claim 16, wherein the culture is contacted with the one or more second agents after contact with the one or more first agents.

27. The method of claim 16, wherein the culture is contacted with the one or more second agents simultaneously with contact with the one or more first agents.

28. The method of claim 16, which further comprises culturing human pluripotent stem cells under conditions that generate cardiac progenitor cells (CPCs), wherein said conditions comprise activation of Wnt/β

-catenin signaling on day 0, followed by inhibition of Wnt/β

-catenin signaling from day 3 to day 5, to obtain a culture of day 5-7 CPCs prior to contacting the culture of day 5-7 CPCs with one or more first agents reactive with at least one first marker that is expressed on the surface of human pluripotent stem cells and not expressed on the surface of CPCs.